Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ClinicalTrials.gov ID: NCT03957252

Clinical study to validate ClarityDX Prostate as a reflex test to high PSA levels to refine prediction of clinically significant prostate cancer has begun in a prospective cohort of 2800 men.